Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________ FORM 10-K __________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Nu ...

Shares of Editas Medicine (EDIT) have gained 0.7% over the past four weeks to close the last trading session at $8.15, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.67 indicates a potential upside of 80%.The average comprises 12 short-term price targets ranging from a low of $7 to a high of $27, with a standard deviation of $6.69. While the lowest estimate indicates a decl ...

Editas Medicine, Inc. (NASDAQ:EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 8:40 AM ET Company Participants Dr. Baisong Mei - Senior Vice President and Chief Medical Officer Conference Call Participants Jay Olson - Oppenheimer Jay Olson Hello everyone and welcome to Oppenheimer’s 34th Annual Healthcare Conference. I am Jay Olson, one of the biotech analysts at Oppenheimer and I want to thank you for joining us. It's my pleasure to welcome Editas to our conference, and i ...

Quite a few bigwigs in the biotech sector have reported results for the fourth quarter and the picture is ordinary. While results have been mixed, the outlook provided by most of these companies is encouraging, indicating bright prospects driven by new drug approvals and positive pipeline updates. The macroeconomic environment, however, remains uncertain and growth might be sluggish.Meanwhile, biotech companies are in the spotlight as pharma/biotech giants are now looking to bolster their product portfolios ...

Editas Medicine, Inc. (NASDAQ:EDIT) Guggenheim 6th Annual Biotechnology Conference February 7, 2024 9:30 AM ET Company Participants Gilmore O'Neill - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Debjit Chattopadhyay Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I'm Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O'Neill. Thank you so much for your time, Gilmore. And if we could star ...

Editas Medicine, Inc. (NASDAQ:EDIT) Guggenheim 6th Annual Biotechnology Conference February 7, 2024 9:30 AM ET Company Participants Gilmore O'Neill - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Debjit Chattopadhyay Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I'm Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O'Neill. Thank you so much for your time Gilmore. And if we could start ...

Editas Medicine (EDIT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a cha ...

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel: Guggenheim 6th Annual Biotechnology ConferenceFormat: Fireside ChatDate: Wednesday, February 7Time: 9:30 a.m. ETLocation: New York, NY Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Fireside ChatDate: Tues ...

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over the long run if they become successful. Just think: What if you had invested in a massively successful biotech giant like Vertex Pharmaceuticals in its early days?Let's look at two relatively small biotechs that, if enough goes right, could deliver outsize returns to those who invest now: Editas Medicine (EDIT - ...

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (EDIT -0.98%) have collapsed by about 88% over the past three years despite recent positive news regarding its experimental therapies and intellectual property.Editas is driving its first CRISPR-based therapy toward commercialization. Following approval of a similar treatment from CRISPR Therapeutics and partner Vertex Pha ...